The company said it expects core molecular testing revenue between $115 million and $125 million and SARS-CoV-2 revenue between $15 million and $20 million.
The company, which went public in June, has had to deal with issues with the US DOJ, and some private insurers. Its CEO's tenure at Sequenom was also marred by a scandal.
Using exome-enriched RNA sequencing and machine learning, researchers tracked down a set of circulating maternal transcripts for predicting severe early-onset preeclampsia.
Under a two-year partnership, the companies plan to discover targets and disease mechanisms for infertility and pregnancy-related conditions, including preeclampsia.
The companies plan to explore opportunities to use Thermo Fisher's LC-MS instrumentation to develop tools to determine the risk for adverse pregnancy outcomes.